Medical/Pharmaceuticals
Menarini Group's Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer
* Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be availablefor patients suffering from 2L and 3L ER+/HER2- advanced or metastatic breast cancer * Submission supported by results from the pivotal Phase 3 EMERALD study of elacestrantshowing st...
2022-08-11 20:08
5163
Everest Medicines Announces Regulatory Update and Strategic Partnership for Xerava™ in Taiwan
Taiwan FDA accepts New Drug Application for Xerava for treatment of cIAI
Everest enters into strategic partnership with TTY Biopharm for the
commercialization of Xerava inTaiwan
SHANGHAI, Aug. 11, 2022 /PRNewswire/ -- Everest Medicines
2022-08-11 08:00
4814
Panacell Biotech to conduct toxicity tests for NK cells, exosomes, and brown adipose-derived stem cells to treat patients with long COVID
SEOUL, South Korea, Aug. 10, 2022 /PRNewswire/ -- Panacell Biotech Co., Ltd.
said that NK cells, exosomes, and brown adipose-derived stem cells are
effective to treat patients with long COVID conditions, or post COVID-19
conditions, as well as those with terminal illness.
2022-08-10 22:00
3836
WeTrade Group Entered Into A Strategic Partnership With Jiqing, Acquiring Monkeypox Test Kits Exclusive Sales Channel
BEIJING, Aug. 10, 2022 /PRNewswire/ -- WeTrade Group Inc. ("WeTrade" or the "Company") (NASDAQ: WETG), an emerging growth company engaged in the business of providing software-as-a-services (SAAS) and cloud intelligent systems for micro-businesses, officially singed the strategic partnership agre...
2022-08-10 20:36
3127
UC Davis' new research shows how total-body PET imaging can assess the immunological response to COVID-19 infections
HOUSTON, Aug. 10, 2022 /PRNewswire/ -- UC Davis, a leading university in molecular imaging that collaborated with United Imaging to develop the world's first total-body PET/CT scanner, 'uEXPLORER®,' recently presented their research on COVID-19 at the 2022 Society of Nuclear Medicine and Molecula...
2022-08-10 20:00
6504
Arbele Announces Phase 1 First-in-Human Study of CDH17xCD3 Bispecific T-Cell Engager for Treatment of Gastrointestinal Cancers
SEATTLE, Aug. 10, 2022 /PRNewswire/ -- Arbele, a clinical stage biopharmaceutical company, announces the successful dosing of the first patient inAustralia in Phase I Study of ARB202, for the treatment of advanced gastrointestinal cancers patients. Globally, Arbele is the first company exploring...
2022-08-10 20:00
2537
Asieris Appoints Dr. Badrinath Konety to Scientific Advisory Board
An expert in genitourinary oncology, Dr. Konety brings deep academic insight, broad clinical expertise and a global network to help Asieris advance its innovative pipeline to serve patients worldwide. SHANGHAI, Aug. 10, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (stock code: 688176.SH), a glob...
2022-08-10 16:09
2365
Recbio announces Phase III Clinical Trial Progress Of Recombinant HPV 9-Valent Vaccine
TAIZHOU, China, Aug. 10, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Company", together with its subsidiaries, the "Group", Stock code: 02179.HK) is pleased to announce that, the Company has recently completed the subject enrollment and first dose vaccination in respect of immun...
2022-08-10 16:06
4092
Starpharma signs new DEP® agreement with MSD
MELBOURNE, Australia, Aug. 10, 2022 /PRNewswire/ -- Australian biotechnology company Starpharma today announced it has signed a new DEP® Research Agreement with MSD, the trade name of Merck Sharp & Dohme LLC,Rahway, NJ, USA. This new DEP® program will generate and evaluate additional DEP® Antibod...
2022-08-10 15:29
2725
Full-Life Technologies Deepens Radioisotope Technology Expertise with Key Leadership Appointments and the Establishment of a Radioisotope Technology Advisory Board
Co-founder and Board Member Hong-hoi Ting, D.Phil. Appointed Chief Strategy Officer James McCarter, Ph.D. Named Vice President, Head of Radioisotope Technology Research William Diamond, Ph.D., Carl Ross, Ph.D. and Herbert Moore, Ph.D. Join Radioisotope Technology Advisory Board SHANGHAI and BR...
2022-08-10 12:00
2409
Bridge Biotherapeutics Presents Promising Interim Clinical Study Results from Phase 1 Study of BBT-176 at WCLC 2022
* The study confirmed preliminary efficacy and safety of BBT-176 along with its treatment responses in advanced NSCLC patients * A patient with the C797S triple mutation showed up to 53 percent reduction in EGFR mutant allelic change VIENNA and SEONGNAM, South Korea, Aug. 9, 2022 /PRNewswire/...
2022-08-10 11:43
2771
MedAlliance SELUTION SLR Receives Second FDA IDE Approval
GENEVA, Aug. 10, 2022 /PRNewswire/ -- SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial for the treatment of occlusive disease of the superficial femoral artery (SFA). ...
2022-08-10 10:00
4172
iNtRON developed New CRISPR/Cas technology specific for Bacteriophage as PHAGERUS® Platform
* CRISPR/Cas system for bacteria that are not E. coli or Streptococcus pyogenes * Customized gene editing technology for unique modified-bacteriophages * To validate efficacy of SARS-CoV-2 mimotopes loaded PHAGERUS® platform BOSTON and SEOUL, South Korea, Aug. 9, 2022 /PRNewswire/ -- iNtRON ...
2022-08-10 09:00
2314
Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Moderate-to-severe Plaque Psoriasis Met Primary Endpoint
SAN FRANCISCO and SUZHOU, China, Aug. 10, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...
2022-08-10 08:00
4726
ONESIGHT ESSILORLUXOTTICA FOUNDATION ANNOUNCES PUBLICATION OF NEW ARTICLE
Article addresses role of advocacy in advancing healthy vision to meet Sustainable Development Goals DALLAS, Aug. 10, 2022 /PRNewswire/ -- OneSight EssilorLuxottica Foundation (Foundation) is pleased to announce the publication of a peer-reviewed article, The Power of Advocacy: Advancing Vision f...
2022-08-10 02:00
3331
Frost & Sullivan Institute Recognizes Samsung Biologics with the 2022 Global Enlightened Growth Leadership Award for its Commitment to Sustainable Growth
Samsung Biologics' mission to create a better world through high-quality biopharmaceuticals is underscored by a series of global initiatives to deliver progress related to climate change SAN ANTONIO, Aug. 9, 2022 /PRNewswire/ -- Frost & Sullivan Institute is proud to present Samsung Biologics wi...
2022-08-09 21:17
3349
Merck Becomes One of the First CDMOs to Provide Full Viral Vector Offering with Launch of VirusExpress® 293 Adeno-Associated Virus Production Platform
* Reduces process development time by an estimated 40 percent * Enables biopharmaceutical companies to increase the speed to clinical manufacturing * Adds to company's best-in-class VirusExpress® Lentiviral Production Platform DARMSTADT,Germany, Aug. 9, 2022 /PRNewswire/ -- Merck, a leading s...
2022-08-09 20:00
4603
Novaliq submits New Drug Application seeking approval for first-of-a-kind Dry Eye Disease Treatment CyclASol®
HEIDELBERG, Germany, and CAMBRIDGE, MA, Aug. 9, 2022 /PRNewswire/ -- Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced the submission of a New Drug Application (NDA) to the U.S. Food and...
2022-08-09 19:00
3280
Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in China
SUZHOU, China, Aug. 9, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company has completed the enrollment and dosing of 92 subjec...
2022-08-09 17:00
3245
Harbour BioMed to Announce 2022 Interim Results on August 31, 2022
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 9, 2022 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142) announced that it will report financial results for the first half year endedJune 30, 2022, on Wednesday, August 31, 2022. The Company will host an English virtual ...
2022-08-09 15:00
2596
Week's Top Stories
Most Reposted
Visa and Marina Bay Precinct Partners - Marina Bay Sands, UOB and Singapore Tourism Board - Present 'A Moment to Savour', Bringing International Restaurant Collaborations to Singapore
[Picked up by 307 media titles]
2026-10-27 13:40
HLB Customers Can Now Scan & Pay in China with HLB QR Pay
[Picked up by 296 media titles]
2026-10-22 22:35
TCL Zhonghuan Powers India's Energy Transition with PV Innovations at REI Expo 2026
[Picked up by 281 media titles]
2026-10-23 21:52
Infobip and Yamaha Power Conversational Customer Engagement in Indonesia's Automotive Sector
[Picked up by 278 media titles]
2026-10-21 15:00
DayOne Supports NVIDIA DSX POD Reference Design, Advancing Standardized Infrastructure for AI
[Picked up by 271 media titles]
2026-10-22 11:55Most Read
Hi3D V1.0 Goes Open Source: The First Production-Validated Open-Source AI 3D Model
2026-10-23 23:30
36572
Home 3D Printers are More Accessible Than Ever This Black Friday with Bambu Lab
2026-10-22 17:00
35733
BeautyPlus Web Launches Halloween Photo Booth With Behind-the-Scenes Video Export
2026-10-23 01:00
34483
Cuttable Unveils Next-Generation AI Advertising Platform as U.S. Expansion Accelerates
2026-10-24 00:00
28871
SwitchBot Launches AI Art Frame 2 with Full-Color E Ink and Personalized Art
2026-10-27 21:00
17778
